Acceptability of palliative sleeve lobectomy with microscopic margin disease in patients with non–small cell lung cancer: A retrospective study
Authors:
Open Access
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Randomized phase II trial of pemetrexed-cisplatin plus bevacizumab or thoracic radiotherapy followed by surgery for stage IIIA (N2) nonsquamous non–small cell lung cancerThe Journal of Thoracic and Cardiovascular Surgery, 2022
- The outcomes of margin status after sleeve lobectomy for patients of non–small cell lung cancerThoracic Cancer, 2022
- Radiation exposure elicits a neutrophil-driven response in healthy lung tissue that enhances metastatic colonizationNature Cancer, 2022
- Postoperative Radiation Therapy Should Not Be Used for the Therapy of Stage III-N2 NSCLCJournal of Thoracic Oncology, 2022
- Postoperative Radiation Therapy Should Be Used for Completely Resected Stage III-N2 NSCLC in Select PatientsJournal of Thoracic Oncology, 2022
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesCA: A Cancer Journal for Clinicians, 2021
- Clinical outcomes of microscopic residual disease after bronchial sleeve resection for non–small cell lung cancerThe Journal of Thoracic and Cardiovascular Surgery, 2021
- Sleeve lobectomy versus pneumonectomy for lung cancer: a comparative analysis of survival and sites or recurrencesThe Annals of Thoracic Surgery, 2004
- Personal experience in lung cancer sleeve lobectomy and sleeve pneumonectomyThe Annals of Thoracic Surgery, 2002
- Successful Removal of an Entire Lung for Carcinoma of the BronchusJAMA, 1984